7th Annual Global Fatty Liver Day is less than 3 months away!

7th Annual Global Fatty Liver Day is less than 3 months away!

Fatty liver disease is a widespread issue that often goes undetected until it’s too late. It impacts millions worldwide leading to missed opportunities for early intervention and prevention. Studies highlight a concerning gap in identifying patients within the healthcare system who may have fatty liver disease unknowingly. We cannot afford to overlook the silent nature of this and this is why we are advocating for immediate action.

read more
Media Kit: Preparing for First US Approval of NASH Therapy

GLI Commends Repurposed Livmarli’s FDA Approval for Patients over 5 with PFIC

(Washington, D.C. March 14, 2024) –Global Liver Institute (GLI) celebrates a win for rare disease patients with the breaking news of the U.S. FDA’s approval for Mirum Pharmaceuticals’ Livmarli to treat cholestasis pruritus in patients 5 and older that have been diagnosed with progressive familial intrahepatic cholestasis (PFIC), a rare, genetic disorder in which bile builds up in the liver.

read more